×
S&P 500   4,129.47 (+1.77%)
DOW   32,984.30 (+1.06%)
QQQ   306.55 (+2.41%)
AAPL   148.46 (+3.25%)
MSFT   271.97 (+2.28%)
FB   193.25 (+0.85%)
GOOGL   2,233.12 (+3.58%)
AMZN   2,259.88 (+1.73%)
TSLA   752.30 (+6.30%)
NVDA   185.00 (+3.64%)
BABA   93.75 (-0.77%)
NIO   16.47 (+2.74%)
AMD   100.75 (+2.03%)
CGC   4.76 (-14.23%)
MU   72.72 (+3.00%)
T   21.34 (+0.09%)
GE   77.95 (+1.22%)
F   13.46 (+2.59%)
DIS   107.97 (+2.23%)
AMC   12.97 (+6.05%)
PFE   53.77 (-0.41%)
PYPL   83.60 (+3.95%)
NFLX   193.29 (+0.99%)
S&P 500   4,129.47 (+1.77%)
DOW   32,984.30 (+1.06%)
QQQ   306.55 (+2.41%)
AAPL   148.46 (+3.25%)
MSFT   271.97 (+2.28%)
FB   193.25 (+0.85%)
GOOGL   2,233.12 (+3.58%)
AMZN   2,259.88 (+1.73%)
TSLA   752.30 (+6.30%)
NVDA   185.00 (+3.64%)
BABA   93.75 (-0.77%)
NIO   16.47 (+2.74%)
AMD   100.75 (+2.03%)
CGC   4.76 (-14.23%)
MU   72.72 (+3.00%)
T   21.34 (+0.09%)
GE   77.95 (+1.22%)
F   13.46 (+2.59%)
DIS   107.97 (+2.23%)
AMC   12.97 (+6.05%)
PFE   53.77 (-0.41%)
PYPL   83.60 (+3.95%)
NFLX   193.29 (+0.99%)
S&P 500   4,129.47 (+1.77%)
DOW   32,984.30 (+1.06%)
QQQ   306.55 (+2.41%)
AAPL   148.46 (+3.25%)
MSFT   271.97 (+2.28%)
FB   193.25 (+0.85%)
GOOGL   2,233.12 (+3.58%)
AMZN   2,259.88 (+1.73%)
TSLA   752.30 (+6.30%)
NVDA   185.00 (+3.64%)
BABA   93.75 (-0.77%)
NIO   16.47 (+2.74%)
AMD   100.75 (+2.03%)
CGC   4.76 (-14.23%)
MU   72.72 (+3.00%)
T   21.34 (+0.09%)
GE   77.95 (+1.22%)
F   13.46 (+2.59%)
DIS   107.97 (+2.23%)
AMC   12.97 (+6.05%)
PFE   53.77 (-0.41%)
PYPL   83.60 (+3.95%)
NFLX   193.29 (+0.99%)
S&P 500   4,129.47 (+1.77%)
DOW   32,984.30 (+1.06%)
QQQ   306.55 (+2.41%)
AAPL   148.46 (+3.25%)
MSFT   271.97 (+2.28%)
FB   193.25 (+0.85%)
GOOGL   2,233.12 (+3.58%)
AMZN   2,259.88 (+1.73%)
TSLA   752.30 (+6.30%)
NVDA   185.00 (+3.64%)
BABA   93.75 (-0.77%)
NIO   16.47 (+2.74%)
AMD   100.75 (+2.03%)
CGC   4.76 (-14.23%)
MU   72.72 (+3.00%)
T   21.34 (+0.09%)
GE   77.95 (+1.22%)
F   13.46 (+2.59%)
DIS   107.97 (+2.23%)
AMC   12.97 (+6.05%)
PFE   53.77 (-0.41%)
PYPL   83.60 (+3.95%)
NFLX   193.29 (+0.99%)
NASDAQ:GLMD

Galmed Pharmaceuticals (GLMD) Stock Forecast, Price & News

$0.52
-0.01 (-1.85%)
(As of 05/27/2022 11:41 AM ET)
Add
Compare
Today's Range
$0.52
$0.52
50-Day Range
$0.50
$1.77
52-Week Range
$0.50
$4.08
Volume
4,977 shs
Average Volume
111,373 shs
Market Capitalization
$13.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.77
30 days | 90 days | 365 days | Advanced Chart
Receive GLMD News and Ratings via Email

Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Galmed Pharmaceuticals logo

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Galmed Pharmaceuticals Ltd. has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.

Headlines

Galmed Pharmaceuticals Shares Down 16%
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GLMD
Employees
18
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$0.97 per share

Profitability

Net Income
$-32.47 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$13.05 million
Optionable
Optionable

Company Calendar

Last Earnings
5/17/2022
Today
5/27/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.85 out of 5 stars

Medical Sector

753rd out of 1,424 stocks

Pharmaceutical Preparations Industry

364th out of 681 stocks

Analyst Opinion: 3.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -













Galmed Pharmaceuticals (NASDAQ:GLMD) Frequently Asked Questions

Is Galmed Pharmaceuticals a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Galmed Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLMD, but not buy additional shares or sell existing shares.
View analyst ratings for Galmed Pharmaceuticals
or view top-rated stocks.

Are investors shorting Galmed Pharmaceuticals?

Galmed Pharmaceuticals saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 23,200 shares, a decrease of 27.3% from the April 30th total of 31,900 shares. Based on an average daily volume of 92,000 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.1% of the shares of the company are sold short.
View Galmed Pharmaceuticals' Short Interest
.

When is Galmed Pharmaceuticals' next earnings date?

Galmed Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Galmed Pharmaceuticals
.

How were Galmed Pharmaceuticals' earnings last quarter?

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) released its earnings results on Tuesday, May, 17th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating analysts' consensus estimates of ($0.32) by $0.08.
View Galmed Pharmaceuticals' earnings history
.

What price target have analysts set for GLMD?

2 Wall Street analysts have issued 1 year price objectives for Galmed Pharmaceuticals' shares. Their forecasts range from $5.00 to $5.00. On average, they expect Galmed Pharmaceuticals' share price to reach $5.00 in the next twelve months. This suggests a possible upside of 861.2% from the stock's current price.
View analysts' price targets for Galmed Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Galmed Pharmaceuticals' key executives?
Galmed Pharmaceuticals' management team includes the following people:
  • Mr. Allen Baharaff, Co-Founder, Pres, CEO & Chairman (Age 57, Pay $766.58k)
  • Mr. Guy Nehemya, Chief Operating Officer (Age 37, Pay $167.54k)
  • Mr. Yohai Stenzler CPA, Chief Accounting Officer (Age 39, Pay $167.26k)
  • Dr. Liat Hayardeny, Chief Scientific Officer (Age 55, Pay $215.45k)
  • Dr. Tali Gorfine, Medical Consultant (Age 52, Pay $202.76k)
  • Mr. Doron Cohen, Chief Financial Officer
  • Ms. Yael Hollander, VP of Legal Affairs & Strategy (Age 39)
  • Ms. Shani Ganon, HR Mang.
  • Mr. Niv Alon, Head of PMO
  • Ms. Topaz Falkoviz Arbel, Corp. Sec.
What other stocks do shareholders of Galmed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include OPKO Health (OPK), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rite Aid (RAD), Exelixis (EXEL), Ocular Therapeutix (OCUL), TG Therapeutics (TGTX), TherapeuticsMD (TXMD) and Corbus Pharmaceuticals (CRBP).

What is Galmed Pharmaceuticals' stock symbol?

Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."

Who are Galmed Pharmaceuticals' major shareholders?

Galmed Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Nantahala Capital Management LLC (1.03%), Raymond James Financial Services Advisors Inc. (0.25%), Cambridge Investment Research Advisors Inc. (0.10%) and Concourse Financial Group Securities Inc. (0.00%).

Which institutional investors are selling Galmed Pharmaceuticals stock?

GLMD stock was sold by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC.

Which institutional investors are buying Galmed Pharmaceuticals stock?

GLMD stock was purchased by a variety of institutional investors in the last quarter, including Raymond James Financial Services Advisors Inc., and Cambridge Investment Research Advisors Inc..

How do I buy shares of Galmed Pharmaceuticals?

Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Galmed Pharmaceuticals' stock price today?

One share of GLMD stock can currently be purchased for approximately $0.52.

How much money does Galmed Pharmaceuticals make?

Galmed Pharmaceuticals has a market capitalization of $13.05 million. The biopharmaceutical company earns $-32.47 million in net income (profit) each year or ($1.180010) on an earnings per share basis.

How many employees does Galmed Pharmaceuticals have?

Galmed Pharmaceuticals employs 18 workers across the globe.

What is Galmed Pharmaceuticals' official website?

The official website for Galmed Pharmaceuticals is www.galmedpharma.com.

How can I contact Galmed Pharmaceuticals?

Galmed Pharmaceuticals' mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company can be reached via phone at (723) 693-8448, via email at [email protected], or via fax at 972-3693-8447.

This page was last updated on 5/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.